Side effects definition

Side effects. The most common side effects reported in the trials were peripheral oedema, nausea, dizziness, fatigue, and ascites. Drug interactions (see also above under cautions): There is no experience regarding administration of rifaximin to subjects who are taking another rifamycin antibacterial agent to treat a systemic bacterial infection. In vitro data show that rifaximin did not inhibit the major cytochrome P-450 (CYP) drug metabolizing enzymes (CYPs1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4). In in vitro induction studies, rifaximin did not induce CYP1A2 and CYP 2B6 but was a weak inducer of CYP3A4. In healthy subjects, clinical drug interaction studies demonstrated that rifaximin did not significantly affect the pharmacokinetics of CYP3A4 substrates, however, in hepatic impaired patients it cannot be excluded that rifaximin may decrease the exposure of concomitant CYP3A4 substrates administered (e.g. warfarin, antiepileptics, antiarrhythmics), due to the higher systemic exposure with respect to healthy subjects. An in vitro study suggested that rifaximin is a moderate substrate of P-glycoprotein (P-gp) and metabolized by CYP3A4. It is unknown whether concomitant drugs which inhibit P-gp and/or CYP3A4 can increase the systemic exposure of rifaximin. The potential for drug-drug interactions to occur at the level of transporter systems has been evaluated in vitro and these studies suggest that a clinical interaction between rifaximin and other compounds that undergo efflux via P-gp and other transport proteins is unlikely (MDR1, MRP2, MRP4, BCRP and BSEP). Annual Cost: £259.23 per person (Drug Tariff Dec 2019)
View Source
Side effects. The most common adverse events with leflunomide treatment in clinical trials were gastrointestinal effects, pruritus, rash, hypertension, alopecia and liver enzyme elevations. Post-marketing, there have been rare reports of serious hepatic reactions and pancytopenia. See the SPC for more details on adverse events. Leflunomide does not have black triangle (▼) status. All serious suspected adverse reactions (even well recognised or causal link uncertain) should be reported to the MHRA. Drug interactions: Recent treatment with hepatotoxic or haematotoxic (eg.methotrexate) drugs may result in increased side effects; care should be taken when initiating leflunomide therapy. Switching to another DMARD after leflunomide treatment may raise the possibility of additive risks because of its long half-life. A washout period is required. Patients treated with leflunomide should not receive concomitant treatment with cholestyramine or activated powdered charcoal, because this leads to rapid and significant decreases in plasma leflunomide concentration.
View Source
Side effects. The most frequent and very common adverse reactions related to propafenone therapy are dizziness, cardiac conduction disorders and palpitations. Refer to SPC for full side-effect profile Propafenone does not have black triangle (▼) status. All serious suspected adverse reactions (even well recognised or causal link uncertain) should be reported to the MHRA.
View Source

Examples of Side effects in a sentence

  • Side effects and their management Side effects are rare with occasional use of Paracetamol.

  • Contra-indications: None Side effects: Mild or moderate vaginal bleeding may occur in girls in the first month of treatment.

  • If patients experience side-effects, discontinue treatment immediately and contact their GP Side -effects can be reduced by dividing the dose.

  • Side effects and their management Side effects are rare with occasional use of paracetamol.

  • Side effects may include pain associated with injection, local pain and aching, priapism (persistent prolonged erections), fibrosis (build-up of scar tissue) and bleeding.

  • Side effects are common, and are frequently caused by unstable anticoagulation.

  • Side effects may include: floaters for a few days post injection, blurred vision in the immediate post operative period, and an increase in eye pressure in patients with glaucoma.

  • Side effects of carboplatin (CBDCA) include myelosuppression, nausea, vomiting, abdominal pain, diarrhea, and constipation.

  • Side effects may include: stinging and burning, double vision, redness and bruising around the injection site, weak or shallow breathing; fast heart rate, gasping, feeling unusually hot; slow heart rate, weak pulse; feeling restless or anxious, ringing in the ears, metallic taste, speech problems, numbness or tingling around your mouth, tremors, feeling light-headed, or fainting; or problems with urination and allergic reactions.

  • Side effects: Most common adverse effects were gastrointestinal events.


More Definitions of Side effects

Side effects. Chest wall rigidity, hypotension, hypoventilation Drug Interactions: When given with amiodarone can cause severe bradycardia, sinus arrest, and hypotension.
View Source
Side effects. Very common: somnolence, headache, abdominal pain, fatigue. Common: decreased appetite, depression, anxiety, affect lability, insomnia, middle insomnia, nightmare, sedation, dizziness, lethargy, bradycardia, hypotension, orthostatic hypotension, vomiting, diarrhoea, nausea, constipation, abdominal/stomach discomfort, dry mouth, rash, enuresis, irritability, decreased blood pressure, increase in weight. See SPC for full list.
View Source

Related to Side effects

  • Fundamental Change Effective Date means the date on which any Fundamental Change becomes effective.

  • the Effective Date means each date that the Registration Statement and any post-effective amendment or amendments thereto became or become effective. "Execution Time" shall mean the date and time that this Agreement is executed and delivered by the parties hereto. "Basic Prospectus" shall mean the form of basic prospectus relating to the Securities contained in the Registration Statement at the Effective Date. "Prospectus" shall mean the Basic Prospectus as supplemented by the Prospectus Supplement. "Registration Statement" shall mean the Registration Statement referred to in paragraph (a) above, including incorporated documents, exhibits and financial statements, as amended at the Execution Time. "Rule 415" and "Rule 424" refer to such rules under the Act. Any reference herein to the Registration Statement, the Basic Prospectus, the Prospectus Supplement or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 which were filed under the Exchange Act on or before the Effective Date or the issue date of the Basic Prospectus, the Prospectus Supplement or the Prospectus, as the case may be; and any reference herein to the terms "amend", "amendment" or "supplement" with respect to the Registration Statement, the Basic Prospectus, the Prospectus Supplement or the Prospectus shall be deemed to refer to and include the filing of any document under the Exchange Act after the Effective Date or the issue date of the Basic Prospectus, the Prospectus Supplement or the Prospectus, as the case may be, deemed to be incorporated therein by reference.

  • Release Effective Date means the date the Release becomes effective and irrevocable.

  • Make-Whole Fundamental Change Effective Date means (A) with respect to a Make-Whole Fundamental Change pursuant to clause (A) of the definition thereof, the date on which such Make-Whole Fundamental Change occurs or becomes effective; and (B) with respect to a Make-Whole Fundamental Change pursuant to clause (B) of the definition thereof, the applicable Redemption Notice Date.

  • Programme Effective Date means 5 December 2017.